S.C. Ropharma S.A.

BVB:RPH Stock Report

Market Cap: RON 75.7m

S.C. Ropharma Management

Management criteria checks 2/4

S.C. Ropharma's CEO is Mihai Miron, appointed in Jan 2009, has a tenure of 16.25 years. directly owns 20.51% of the company’s shares, worth RON15.52M. The average tenure of the management team and the board of directors is 15.3 years and 18.3 years respectively.

Key information

Mihai Miron

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure16.3yrs
CEO ownership20.5%
Management average tenure15.3yrs
Board average tenure18.3yrs

Recent management updates

Recent updates

S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On Capital

Dec 06
S.C. Ropharma (BVB:RPH) Is Experiencing Growth In Returns On Capital

Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On Capital

Dec 09
Here's What's Concerning About S.C. Ropharma's (BVB:RPH) Returns On Capital

S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of Return

Sep 23
S.C. Ropharma (BVB:RPH) Is Reinvesting At Lower Rates Of Return

Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?

Jun 01
Is S.C. Ropharma (BVB:RPH) Using Too Much Debt?

Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On Capital

Mar 16
Some Investors May Be Worried About S.C. Ropharma's (BVB:RPH) Returns On Capital

S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of Debt

May 15
S.C. Ropharma (BVB:RPH) Takes On Some Risk With Its Use Of Debt

S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital Effectively

Mar 26
S.C. Ropharma (BVB:RPH) Might Be Having Difficulty Using Its Capital Effectively

Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?

Dec 23
Should You Be Impressed By S.C. Ropharma's (BVB:RPH) Returns on Capital?

We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A Guide

Nov 24
We Wouldn't Rely On S.C. Ropharma's (BVB:RPH) Statutory Earnings As A Guide

CEO

Mihai Miron (64 yo)

16.3yrs

Tenure

Dr. Pharmacist. Mihai Miron serves as Chairman since 2009 and Chief Executive Officer of Ropharma SA.

Leadership Team

NamePositionTenureCompensationOwnership
Mihai Miron
Chairman of the Board of Directors16.3yrsno data20.51%
RON 15.5m
Alin Radasanu
CFO & Member of the Board of Directors15.3yrsno data0.030%
RON 22.4k
Danut Ene
HR Director & Member of Board of Directors13.3yrsno data0.30%
RON 226.3k

15.3yrs

Average Tenure

56yo

Average Age

Experienced Management: RPH's management team is seasoned and experienced (15.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mihai Miron
Chairman of the Board of Directors16.3yrsno data20.51%
RON 15.5m
Alin Radasanu
CFO & Member of the Board of Directors18.3yrsno data0.030%
RON 22.4k
Danut Ene
HR Director & Member of Board of Directors18.3yrsno data0.30%
RON 226.3k
Florentina Miron
Member of the Board of Directors18.3yrsno data1.38%
RON 1.0m
Doru Vasile Darabus
Member of the Board of Directors16.3yrsno data0.30%
RON 227.4k
Mihai Bratescu
Member of the Board of Directors18.3yrsno data1.13%
RON 853.7k
Ovidiu Nut
Member of the Board of Directors9yrsno data0.030%
RON 22.9k

18.3yrs

Average Tenure

63yo

Average Age

Experienced Board: RPH's board of directors are seasoned and experienced ( 18.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/17 05:28
End of Day Share Price 2025/04/17 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

S.C. Ropharma S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Roxana DascaluSSIF IEBA Trust SA